Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Where can you publish?
Find journals in COLORADO Profiles by department and year.

Contact Us
If you have any questions or feedback please contact us.

Janet Marie Wenzlau

TitleResearch Instructor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Immunology Microbiology
Phone303/724-6815

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lahner E, Brigatti C, Marzinotto I, Carabotti M, Scalese G, Davidson HW, Wenzlau JM, Bosi E, Piemonti L, Annibale B, Lampasona V. Luminescent Immunoprecipitation System (LIPS) for Detection of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton Pump H+,K+-ATPase in Atrophic Body Gastritis Patients. Clin Transl Gastroenterol. 2017 Jan 19; 8(1):e215.
      View in: PubMed
    2. Rusak E, Chobot A, Krzywicka A, Wenzlau J. Anti-parietal cell antibodies - diagnostic significance. Adv Med Sci. 2016 Sep; 61(2):175-179.
      View in: PubMed
    3. Wenzlau JM, Frisch LM, Hutton JC, Fain PR, Davidson HW. Changes in Zinc Transporter 8 Autoantibodies Following Type 1 Diabetes Onset: The Type 1 Diabetes Genetics Consortium Autoantibody Workshop. Diabetes Care. 2015 Oct; 38 Suppl 2:S14-20.
      View in: PubMed
    4. Wenzlau JM, Fain PR, Gardner TJ, Frisch LM, Annibale B, Hutton JC. ATPase4A Autoreactivity and Its Association With Autoimmune Phenotypes in the Type 1 Diabetes Genetics Consortium Study. Diabetes Care. 2015 Oct; 38 Suppl 2:S29-36.
      View in: PubMed
    5. Brorsson CA, Onengut S, Chen WM, Wenzlau J, Yu L, Baker P, Williams AJ, Bingley PJ, Hutton JC, Eisenbarth GS, Concannon P, Rich SS, Pociot F. Novel Association Between Immune-Mediated Susceptibility Loci and Persistent Autoantibody Positivity in Type 1 Diabetes. Diabetes. 2015 Aug; 64(8):3017-27.
      View in: PubMed
    6. Demeester S, Keymeulen B, Kaufman L, Van Dalem A, Balti EV, Van de Velde U, Goubert P, Verhaeghen K, Davidson HW, Wenzlau JM, Weets I, Pipeleers DG, Gorus FK. Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual ß-cell function in recent-onset type 1 diabetes. Diabetes Care. 2015 Apr; 38(4):644-51.
      View in: PubMed
    7. Chobot A, Wenzlau J, Bak-Drabik K, Kwiecien J, Polanska J, Rewers M. ATP4A autoimmunity and Helicobacter pylori infection in children with type 1 diabetes. Clin Exp Immunol. 2014 Sep; 177(3):598-602.
      View in: PubMed
    8. Davidson HW, Wenzlau JM, O'Brien RM. Zinc transporter 8 (ZnT8) and ß cell function. Trends Endocrinol Metab. 2014 Aug; 25(8):415-24.
      View in: PubMed
    9. Asanghanwa M, Gorus FK, Weets I, der Auwera BV, Aminkeng F, Mbunwe E, Goubert P, Verhaeghen K, Sobngwi E, Wenzlau JM, Hutton JC, Pipeleers DG, Keymeulen B, Mbanya JC, van Schravendijk C. Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: relation to autoantibody status and comparison with Belgian patients. Diabetes Res Clin Pract. 2014 Jan; 103(1):97-105.
      View in: PubMed
    10. Wenzlau JM, Hutton JC. Novel diabetes autoantibodies and prediction of type 1 diabetes. Curr Diab Rep. 2013 Oct; 13(5):608-15.
      View in: PubMed
    11. Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK. In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions. Diabetologia. 2013 Sep; 56(9):1964-70.
      View in: PubMed
    12. Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care. 2013 Aug; 36(8):2266-70.
      View in: PubMed
    13. Gorus FK, Balti EV, Vermeulen I, Demeester S, Van Dalem A, Costa O, Dorchy H, Tenoutasse S, Mouraux T, De Block C, Gillard P, Decochez K, Wenzlau JM, Hutton JC, Pipeleers DG, Weets I. Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients. Clin Exp Immunol. 2013 Jan; 171(1):82-90.
      View in: PubMed
    14. Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK. HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients. Diabetes. 2013 Apr; 62(4):1345-50.
      View in: PubMed
    15. Burbelo PD, Lebovitz EE, Bren KE, Bayat A, Paviol S, Wenzlau JM, Barriga KJ, Rewers M, Harlan DM, Iadarola MJ. Extrapancreatic autoantibody profiles in type I diabetes. PLoS One. 2012; 7(9):e45216.
      View in: PubMed
    16. Gottlieb PA, Yu L, Babu S, Wenzlau J, Bellin M, Frohnert BI, Moran A. No relation between cystic fibrosis-related diabetes and type 1 diabetes autoimmunity. Diabetes Care. 2012 Aug; 35(8):e57.
      View in: PubMed
    17. Baker P, Fain P, Kahles H, Yu L, Hutton J, Wenzlau J, Rewers M, Badenhoop K, Eisenbarth G. Genetic determinants of 21-hydroxylase autoantibodies amongst patients of the Type 1 Diabetes Genetics Consortium. J Clin Endocrinol Metab. 2012 Aug; 97(8):E1573-8.
      View in: PubMed
    18. Howson JM, Krause S, Stevens H, Smyth DJ, Wenzlau JM, Bonifacio E, Hutton J, Ziegler AG, Todd JA, Achenbach P. Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia. 2012 Jul; 55(7):1978-84.
      View in: PubMed
    19. Yu L, Boulware DC, Beam CA, Hutton JC, Wenzlau JM, Greenbaum CJ, Bingley PJ, Krischer JP, Sosenko JM, Skyler JS, Eisenbarth GS, Mahon JL. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care. 2012 Jun; 35(6):1213-8.
      View in: PubMed
    20. Vermeulen I, Weets I, Costa O, Asanghanwa M, Verhaeghen K, Decochez K, Ruige J, Casteels K, Wenzlau J, Hutton JC, Pipeleers DG, Gorus FK. An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age. Diabetologia. 2012 Feb; 55(2):413-20.
      View in: PubMed
    21. Wenzlau JM, Frisch LM, Hutton JC, Davidson HW. Mapping of conformational autoantibody epitopes in ZNT8. Diabetes Metab Res Rev. 2011 Nov; 27(8):883-6.
      View in: PubMed
    22. Wenzlau JM, Gardner TJ, Frisch LM, Davidson HW, Hutton JC. Development of a novel autoantibody assay for autoimmune gastritis in type 1 diabetic individuals. Diabetes Metab Res Rev. 2011 Nov; 27(8):887-90.
      View in: PubMed
    23. Lampasona V, Schlosser M, Mueller PW, Williams AJ, Wenzlau JM, Hutton JC, Achenbach P. Diabetes antibody standardization program: first proficiency evaluation of assays for autoantibodies to zinc transporter 8. Clin Chem. 2011 Dec; 57(12):1693-702.
      View in: PubMed
    24. Vermeulen I, Weets I, Asanghanwa M, Ruige J, Van Gaal L, Mathieu C, Keymeulen B, Lampasona V, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK. Contribution of antibodies against IA-2ß and zinc transporter 8 to classification of diabetes diagnosed under 40 years of age. Diabetes Care. 2011 Aug; 34(8):1760-5.
      View in: PubMed
    25. Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, Gottlieb PA, Davidson HW. Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol. 2011 May 15; 186(10):6056-63.
      View in: PubMed
    26. Yang L, Luo S, Huang G, Peng J, Li X, Yan X, Lin J, Wenzlau JM, Davidson HW, Hutton JC, Zhou Z. The diagnostic value of zinc transporter 8 autoantibody (ZnT8A) for type 1 diabetes in Chinese. Diabetes Metab Res Rev. 2010 Oct; 26(7):579-84.
      View in: PubMed
    27. YANG L, LUO SM, HUANG G, PENG J, YAN X, WENZLAU J, DAVIDSON HW, HUTTON JC, ZHOU ZG. [Value of zinc transporter 8 autoantibody in the diagnostic classification of acute-onset diabetics]. Zhonghua Yi Xue Za Zhi. 2010 Sep 28; 90(36):2536-40.
      View in: PubMed
    28. Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, Ziegler AG, Davidson HW, Hutton JC. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab. 2010 Oct; 95(10):4712-9.
      View in: PubMed
    29. Yu L, Liu Y, Miao D, Wenzlau J, Davidson H, Hutton J, Eisenbarth GS. Triple chimeric islet autoantigen IA2-ZnT8WR to facilitate islet autoantibody determination. J Immunol Methods. 2010 Feb 28; 353(1-2):20-3.
      View in: PubMed
    30. De Grijse J, Asanghanwa M, Nouthe B, Albrecher N, Goubert P, Vermeulen I, Van Der Meeren S, Decochez K, Weets I, Keymeulen B, Lampasona V, Wenzlau J, Hutton JC, Pipeleers D, Gorus FK. Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia. 2010 Mar; 53(3):517-24.
      View in: PubMed
    31. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep. 2009 Apr; 9(2):105-12.
      View in: PubMed
    32. Wenzlau JM, Moua O, Liu Y, Eisenbarth GS, Hutton JC, Davidson HW. Identification of a major humoral epitope in Slc30A8 (ZnT8). Ann N Y Acad Sci. 2008 Dec; 1150:252-5.
      View in: PubMed
    33. Liu Y, Wenzlau JM, Yu L, Patel C, Eisenbarth GS, Hutton JC, Davidson HW. Conserved epitopes in the protein tyrosine phosphatase family of diabetes autoantigens. Ann N Y Acad Sci. 2008 Dec; 1150:245-7.
      View in: PubMed
    34. Wenzlau JM, Moua O, Sarkar SA, Yu L, Rewers M, Eisenbarth GS, Davidson HW, Hutton JC. SlC30A8 is a major target of humoral autoimmunity in type 1 diabetes and a predictive marker in prediabetes. Ann N Y Acad Sci. 2008 Dec; 1150:256-9.
      View in: PubMed
    35. Kawasaki E, Uga M, Nakamura K, Kuriya G, Satoh T, Fujishima K, Ozaki M, Abiru N, Yamasaki H, Wenzlau JM, Davidson HW, Hutton JC, Eguchi K. Association between anti-ZnT8 autoantibody specificities and SLC30A8 Arg325Trp variant in Japanese patients with type 1 diabetes. Diabetologia. 2008 Dec; 51(12):2299-302.
      View in: PubMed
    36. Wenzlau JM, Hutton JC, Davidson HW. New antigenic targets in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008 Aug; 15(4):315-20.
      View in: PubMed
    37. Wenzlau JM, Liu Y, Yu L, Moua O, Fowler KT, Rangasamy S, Walters J, Eisenbarth GS, Davidson HW, Hutton JC. A common nonsynonymous single nucleotide polymorphism in the SLC30A8 gene determines ZnT8 autoantibody specificity in type 1 diabetes. Diabetes. 2008 Oct; 57(10):2693-7.
      View in: PubMed
    38. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007 Oct 23; 104(43):17040-5.
      View in: PubMed
    39. Wenzlau JM, Garl PJ, Simpson P, Stenmark KR, West J, Artinger KB, Nemenoff RA, Weiser-Evans MC. Embryonic growth-associated protein is one subunit of a novel N-terminal acetyltransferase complex essential for embryonic vascular development. Circ Res. 2006 Mar 31; 98(6):846-55.
      View in: PubMed
    40. Gerasimovskaya EV, Tucker DA, Weiser-Evans M, Wenzlau JM, Klemm DJ, Banks M, Stenmark KR. Extracellular ATP-induced proliferation of adventitial fibroblasts requires phosphoinositide 3-kinase, Akt, mammalian target of rapamycin, and p70 S6 kinase signaling pathways. J Biol Chem. 2005 Jan 21; 280(3):1838-48.
      View in: PubMed
    41. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation. 2004 Mar 16; 109(10):1299-306.
      View in: PubMed
    42. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res. 2004 Feb 06; 94(2):175-83.
      View in: PubMed
    43. Andres DA, Milatovich A, Ozçelik T, Wenzlau JM, Brown MS, Goldstein JL, Francke U. cDNA cloning of the two subunits of human CAAX farnesyltransferase and chromosomal mapping of FNTA and FNTB loci and related sequences. Genomics. 1993 Oct; 18(1):105-12.
      View in: PubMed
    44. Wenzlau JM, Perlman PS. Mobility of two optional G + C-rich clusters of the var1 gene of yeast mitochondrial DNA. Genetics. 1990 Sep; 126(1):53-62.
      View in: PubMed
    45. Wenzlau JM, Saldanha RJ, Butow RA, Perlman PS. A latent intron-encoded maturase is also an endonuclease needed for intron mobility. Cell. 1989 Feb 10; 56(3):421-30.
      View in: PubMed
    Wenzlau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
    Physical Neighbors
    _

    Copyright © 2012 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.5.1)